AU2001258093A1 - Molecules that modulate ubiquitin-dependent proteolysis and methods for identifying same - Google Patents

Molecules that modulate ubiquitin-dependent proteolysis and methods for identifying same

Info

Publication number
AU2001258093A1
AU2001258093A1 AU2001258093A AU5809301A AU2001258093A1 AU 2001258093 A1 AU2001258093 A1 AU 2001258093A1 AU 2001258093 A AU2001258093 A AU 2001258093A AU 5809301 A AU5809301 A AU 5809301A AU 2001258093 A1 AU2001258093 A1 AU 2001258093A1
Authority
AU
Australia
Prior art keywords
molecules
methods
dependent proteolysis
identifying same
modulate ubiquitin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001258093A
Other languages
English (en)
Inventor
Piers Nash
Tony Pawson
Xiaojing Tang
Mike Tyers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mount Sinai Hospital Corp
Original Assignee
Mount Sinai Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai Hospital Corp filed Critical Mount Sinai Hospital Corp
Publication of AU2001258093A1 publication Critical patent/AU2001258093A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2001258093A 2000-05-04 2001-05-04 Molecules that modulate ubiquitin-dependent proteolysis and methods for identifying same Abandoned AU2001258093A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20216600P 2000-05-04 2000-05-04
US60/202,166 2000-05-04
US26377401P 2001-01-24 2001-01-24
US60/263,774 2001-01-24
PCT/CA2001/000632 WO2001083518A2 (fr) 2000-05-04 2001-05-04 Molecules qui modulent la proteolyse dependant de l'ubiquitine et procedes d'identification de ces molecules

Publications (1)

Publication Number Publication Date
AU2001258093A1 true AU2001258093A1 (en) 2001-11-12

Family

ID=26897420

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001258093A Abandoned AU2001258093A1 (en) 2000-05-04 2001-05-04 Molecules that modulate ubiquitin-dependent proteolysis and methods for identifying same

Country Status (5)

Country Link
US (1) US20040072319A1 (fr)
EP (1) EP1283879A2 (fr)
AU (1) AU2001258093A1 (fr)
CA (1) CA2407945A1 (fr)
WO (1) WO2001083518A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024999A2 (fr) * 2001-09-14 2003-03-27 Novartis Pharma Gmbh Couplage de la proteine f-box, hcdc4, par la cycline e pour une ubiquitinylation et une degradation
EP1426055A1 (fr) * 2002-11-29 2004-06-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Véhicules de dégradation ciblée de protéines, acides nucéiques codants pour ceux-ci et leur utilisation
EP1469082A1 (fr) * 2003-04-16 2004-10-20 Boehringer Ingelheim International GmbH Méthode d'identification de substances qui inhibent spécifiquement le complexe de promotion d'anaphase.
KR101616603B1 (ko) * 2012-10-11 2016-04-28 서울대학교산학협력단 메틸 데그론 펩타이드 및 이를 이용한 단백질 수명 조절 방법
CN104917708B (zh) * 2014-03-13 2018-07-06 通用电气公司 叠加信号采样装置及采样方法
AU2016301195B2 (en) 2015-08-06 2022-09-01 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responses
EP3579847A4 (fr) * 2017-02-08 2020-12-09 Dana Farber Cancer Institute, Inc. Dégradation modulable de protéine endogène avec des composés hétérobifonctionnels
JP7227912B2 (ja) 2017-02-08 2023-02-24 ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド キメラ抗原受容体の調節

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE193123T1 (de) * 1994-01-04 2000-06-15 Mitotix Inc Ubiquitin-konjugierende enzyme
US6573094B1 (en) * 1997-10-16 2003-06-03 Baylor College Of Medicine F-box genes and proteins
US6441140B1 (en) * 1998-09-04 2002-08-27 Cell Signaling Technology, Inc. Production of motif-specific and context-independent antibodies using peptide libraries as antigens
AU1203000A (en) * 1998-10-09 2000-05-01 President And Fellows Of Harvard College Targeted proteolysis by recruitment to ubiquitin protein ligases
WO2003024999A2 (fr) * 2001-09-14 2003-03-27 Novartis Pharma Gmbh Couplage de la proteine f-box, hcdc4, par la cycline e pour une ubiquitinylation et une degradation

Also Published As

Publication number Publication date
WO2001083518A3 (fr) 2002-07-18
WO2001083518A2 (fr) 2001-11-08
US20040072319A1 (en) 2004-04-15
CA2407945A1 (fr) 2001-11-08
EP1283879A2 (fr) 2003-02-19
WO2001083518A9 (fr) 2002-12-05

Similar Documents

Publication Publication Date Title
WO2003032240A8 (fr) Procedes et appareils d'identification
AU2002252550A1 (en) System, method and medium for certifying and accrediting requirements compliance
AU2002227280A1 (en) Protein modification and maintenance molecules
AU2002350109A1 (en) Methods and apparatus for cryo-therapy
AU2002365592A1 (en) Systems and methods for disseminating information
AU2001275112A1 (en) Systems and methods for application service provision
AU3274301A (en) Systems and methods for multiple-file data compression
AU2002357091A1 (en) System and method for music inditification
IL158750A0 (en) Reagents and methods for modulating dkk-mediated interactions
AU2002322458A1 (en) Method for immobilizing molecules onto surfaces
AU2002338428A1 (en) Methods and systems for identifying proteins
AU2001272278A1 (en) Lighting adjustment methods and apparatus for voxel data
AU2001258093A1 (en) Molecules that modulate ubiquitin-dependent proteolysis and methods for identifying same
AU2002366242A1 (en) System and method for identifying media
AU2002364610A1 (en) Methods and materials for modulating trpc4
AU2002318356A1 (en) Protein modification and maintenance molecules
AU1479200A (en) Methods for detecting lower-frequency molecules
AU2001270271A1 (en) Protein modification and maintenance molecules
AU2002238413A1 (en) Device for identifying and locating leakages
AU2002364612A1 (en) METHODS AND MATERIALS FOR MODULATING ENaC-BETA
AU2002253883A1 (en) Protein modification and maintenance molecules
AU2002343515A1 (en) Protein modification and maintenance molecules
AU2000268748A1 (en) Method and apparatus for range finding
AU2002242763A1 (en) Method and apparatus for identifying sounds
AU2001286091A1 (en) Methods for identifying modulators of protein interactions